Tailoring therapy in Waldenström Macroglobulinemia
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.1212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Diego Villa. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Waldenström Macroglobulinemia (WM) is a mature B-cell neoplasm categorized as a lymphoplasmacytic lymphoma (LPL) with monoclonal immunoglobulin M (IgM) production. WM comprises a spectrum of clinical manifestations related to (a) excessive infiltration of the bone marrow and/or other organs (lymph nodes, spleen, extranodal organs) by the LPL infiltrate, and (b) the impact of excess IgM on the circulatory and immune systems, and end organs. The latter includes serum hyperviscosity, infection related to suppression of other immunoglobulins, autoimmune cytopenias, cryoglobulinemia, production of anti-myelin-associated glycoprotein antibodies leading to peripheral neuropathy, and occasionally AL amyloidosis with end-organ deposition.
Zitieren
APA
Villa, D. (2022). Tailoring therapy in Waldenström Macroglobulinemia. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1212
Vancouver
Villa D. Tailoring therapy in Waldenström Macroglobulinemia. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1212
BibTeX
@article{Villa2022,
author = {Villa, Diego},
title = {Tailoring therapy in Waldenström Macroglobulinemia},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.1212}
}
EUVIMED